The Role of Cathepsin K in Normal Bone Resorption

Drug News and Perspectives

Volumn 17, Issue 1, 2004, Pages 19-28

  Troen, Bruce R ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN K; ESTROGEN; GAMMA INTERFERON; GLUCOCORTICOID; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; RETINOIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN D;

DRUG TARGETING; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; IN VITRO STUDY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSCLEROSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; PYKNODYSOSTOSIS; REVIEW; SHORT STATURE;

ANIMALS; BONE RESORPTION; CATHEPSINS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; MICE; MICE, KNOCKOUT; OSTEOCLASTS; OSTEOGENESIS;

EID: 1842581507     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2004.17.1.829022     Document Type: Review

References (145)

1. Riggs, B.L. and Melton, L.D. Involutional osteoporosis. N Engl J Med 1986, 314: 1676-86.
2. Seeman, E. The dilemma of osteoporosis. Am J Med 1995, 98: 76-88S.
3. Riggs, B.L., Khosla, S. and Melton, L.J., III. A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998, 13: 763-73.
4. Manolagas, S.C. and Jilka, R.L. Bone marrow cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995, 332: 305-11.
5. Riggs, B.L., Khosla, S. and Melton, L.J., III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002, 23: 279-302.
6. Troen, B.R. Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol 2003, 38: 605-14.
7. Boyle, W.J., Simonet, W.S. and Lacey, D.L. Osteoclast differentiation and activation. Nature 2003, 423: 337-42.
8. Kodama, H., Yamasaki, A., Nose, M. et al. Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor. J Exp Med 1991, 173: 269-72.
9. Kodama, H., Nose, M., Niida, S. and Yamasaki, A. Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med 1991, 173: 1291-4.
10. Takahashi, N., Udagawa, N. and Suda, T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 1999, 256: 449-55.
11. Lagasse, E. and Weissman, I.L. Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice. Cell 1997, 89: 1021-31.
12. Lacey, D.L., Timms, E., Tan, H.L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93: 165-76.
13. Simonet, W.S., Lacey, D.L., Dunstan, C.R. et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997, 89: 309-19.
14. Yasuda, H., Shima, N., Nakagawa, N. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95: 3597-602.
15. Miura, M., Tanaka, K., Komatsu, Y. et al. A novel interaction between thyroid hormones and 1,25(OH)(2)D(3) in osteoclast formation. Biochem Biophys Res Commun 2002, 291: 987-94.
16. Lee, S.K. and Lorenzo, J.A. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. Endocrinology 1999, 140: 3552-61.
17. Hofbauer, L.C., Lacey, D.L., Dunstan, C.R., Spelsberg, T.C., Riggs, B.L. and Khosla, S. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999, 25: 255-9.
18. Chung, H., Kang, Y.S., Hwang, C.S. et al. Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. J Korean Med Sci 2001, 16: 769-73.
19. Li, X., Pilbeam, C.C., Pan, L., Breyer, R.M. and Raisz, L.G. Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. Bone 2002, 30: 567-73.
20. Aubin, J.E. and Bonnelye, E. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 2000, 11: 905-13.
21. Kikuchi, T., Matsuguchi, T., Tsuboi, N. et al. Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. J Immunol 2001, 166: 3574-9.
22. Suda, K., Takami, M., Udagawa, N. et al. Bacteral CpG-DNA and viral double-stranded RNA stimulate osteoclast formation through lhe induction of RANKL in osteoblasts. J Back Musculoskeletal Rehabil 2002, 17: S346.
23. Deyama, Y., Kikuiri, T., Ohnishi, G. et al. Histamine stimulates production of osteoclast differentiation factor/receptor activator of nuclear factor-kappaB ligand by osteoblasts. Biochem Biophys Res Commun 2002, 298: 240-6.
24. Chikazu, D., Katagiri, M., Ogasawara, T. et al. Regulation of osteoclast differentiation by fibroblast growth factor 2: Stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. J Bone Miner Res 2001, 16: 2074-81.
25. Rubin, J., Ackert-Bicknell, C.L., Zhu, L. et al. IGF-1 regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 2002, 87: 4273-9.
26. Kanematsu, M., Yoshimura, K., Takaoki, M. and Sato, S. Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway. Bone 2002, 30: 553-8.
27. Mizuno, A., Amizuka, N., Irie, K. et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998, 247: 610-5.
28. Viereck, V., Emons, G., Lauck, V. et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002, 291: 680-6.
29. Quinn, J.M., Itoh, K., Udagawa, N. et al. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res 2001, 16: 1787-94.
30. Takai, H., Kanematsu, M., Yano, K. et al. Transforming growth factor-beta stimulates the production of osteoprotegerin/ osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem 1998, 273: 27091-6.
31. Quinn, J.M., Elliott, J., Gillespie, M.T. and Martin, T.J. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998, 139: 4424-7.
32. Gyda, M., Corisdeo, S., Zaidi, M. and Troen, B.R. Macrophage colony-stimulating factor suppresses osteoblast formation. Biochem Biophys Res Commun 2001, 285: 328-34.
33. Tondravi, M.M., McKercher, S.R., Anderson, K. et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.I. Nature 1997, 386: 81-4.
34. Felix, R., Cecchini, M.G. and Fleisch, H. Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology 1990, 127: 2592-4.
35. Grigoriadis, A.E., Wang, Z.Q., Cecchini, M.G. et al. c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994, 266: 443-8.
36. Dougall, W.C., Glaccum, M., Charrier, K. et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999, 13: 2412-24.
37. Iotsova, V., Caamano, J., Loy, J., Yang, Y., Lewin, A. and Bravo, R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997, 3: 1285-9.
38. Lomaga, M.A., Yeh, W.C., Sarosi, I. et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-I. CD40, and LPS signaling. Genes Dev 1999, 13: 1015-24.
39. Soriano, P., Montgomery, C., Geske, R. and Bradley. A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991, 64: 693-702.
40. Chellaiah, M., Kizer, N., Silva, M., Alvarez, U., Kwiatkowski, D. and Hruska, K.A. Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength. J Cell Biol 2000, 148: 665-78.
41. Feng, X., Novack, D.V., Faccio, R. et al. A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function. J Clin Invest 2001, 107: 1137-44.
42. Li, Y.P., Chen, W., Liang, Y., Li, E. and Stashenko, P. Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet 1999, 23: 447-51.
43. Kornak, U., Kasper, D., Bosl, M.R. et al. Loss of the CIC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001, 104: 205-15.
44. Kocher, M.S. and Kasser, J.R. Osteopetrosis. Am J Orthop 2003, 32: 222-8.
45. Hollberg, K., Hultenby, K., Hayman, A., Cox, T. and Andersson. G. Osteoclasts from mice deficient in tartrate-resistant acid phosphatase have altered ruffled borders and disturbed intracellular vesicular transport. Exp Cell Res 2002, 279: 227-38.
46. Saftig, P., Hunziker, E., Wehmeyer, O. et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 1998, 95: 13453-8.
47. Naito, A., Azuma, S., Tanaka, S. et al. Severe osteopetrosis, defective interleukin-I signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999, 4: 353-62.
48. Blair, H.C., Teitelbaum, S.L., Ghiselli, R. and Gluck, S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 1989, 245: 855-7.
49. Saneshige, S., Mano, H., Tezuka, K. et al. Retinoic acid directly stimulates osteoclastic bone resorption and gene expression of cathepsin K/OC-2. Biochem J 1995, 309: 721-4.
50. Vaes, G., Delaisse, J.M. and Eeckhout, Y. Relative roles of collagenase and lysosomal cysteine-proteinases in bone resorption. Matrix 1992, 1: 383-8.
51. Lazner, F., Gowen, M. and Kola, I. An animal model for pycnodysostosis: The role of cathepsin K in bone remodelling. Mol Med Today 1999, 5: 413-4.
52. Delaisse, J.M., Ledent, P. and Vaes, G. Collagenolytic cysteine proteinases of bone tissue. Cathepsin B, (pro)cathepsin L and a cathepsin L-like 70 kDa proteinase. Biochem J 1991: 167-74.
53. Dong, S.S., Stransky, G.I., Whitaker, C.H. et al. Avian cathepsin B cDNA: Sequence and demonstration that mRNAs of two sizes are produced in cell types producing large quantities of the enzyme. Biochim Biophys Acta 1995, 1251: 69-73.
54. Goto, T., Tsukuba, T., Kiyoshima, T. et al. Immunohistochemical localization of cathepsins B, D and L in the rat osteoclast. Histochemistry 1993, 99: 411-4.
55. Goto, S. Molecular biological approaches to aging in Japan: An overview. Arch Gerontol Geriatr 1994, 19: 159-70.
56. Sasaki, T. and Ueno, M.E. Cysteine-proteinase localization in osteoclasts: An immunocytochemical study. Cell Tissue Res 1993, 271: 177-9.
57. Tezuka, K., Tezuka, Y., Maejima, A. et al. Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J Biol Chem 1994, 269: 1106-9.
58. Inaoka, T., Bilbe, G., Ishibashi, O., Tezuka, K., Kumegawa, M. and Kokubo, T. Molecular cloning of human cDNA for cathepsin K: Novel cysteine proteinase pre-dominantly expressed in bone. Biochem Biophys Res Commun 1995, 206: 89-96.
59. Shi, G.P., Chapman, H.A., Bhairi, S.M., DeLeeuw, C., Reddy, V.Y. and Weiss, S.J. Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2. FEBS Lett 1995, 357: 129-34.
60. Gelb, B.D., Moissoglu, K., Zhang, J., Martignetti, J.A., Bromme, D. and Desnick, R.J. Cathepsin K: Isolation and characterization of the murine cDNA and genomic sequence, the homologue of the human pycnodysostosis gene. Biochem Mol Med 1996, 59: 200-6.
61. Rantakokko, J., Aro, H.T., Savontaus, M. and Vuorio, E. Mouse cathepsin K: cDNA cloning and predominant expression of the gene in osteoclasts, and in some hypertrophying chondrocytes during mouse development. FEBS Lett 1996, 393: 307-13.
62. Drake, F.H., Dodds, R.A., James, I.E. et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 1996, 271: 12511-6.
63. Li, Y.P. and Chen, W. Characterization of mouse cathepsin K gene, the gene promoter, and the gene expression. J Bone Miner Res 1999, 14: 487-99.
64. Rantakokko, J., Kiviranta, R., Eerola, R., Aro, H.T. and Vuorio, E. Complete genomic structure of the mouse cathepsin K gene (Ctsk) and its localization next to the Arnt gene on mouse chromosome 3. Matrix Biol 1999, 18: 155-61.
65. Gelb, B.D., Shi, G.P., Heller, M. et al. Structure and chromosomal assignment of the human cathepsin K gene. Genomics 1997, 41: 258-62.
66. Entrez-Genome 2003, posting date. Entrez Genome View - CTSK. [Online.]
67. Berti, P.J. and Storer, A.C. Alignment/phylogeny of the papain superfamily of cysteine proteases. J Mol Biol 1995, 246: 273-83.
68. Dodds, R.A., James, I.E., Rieman, D. et al. Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption. J Bone Miner Res 2001, 16: 478-86.
69. Garnero, P., Borel, O., Byrjalsen, I. et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998, 273: 32347-52.
70. Bromme, D., Okamoto, K., Wang, B.B. and Biroc, S. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem 1996, 271: 2126-32.
71. Li, Z., Hou, W.S., Escalante-Torres, C.R., Gelb, B.D. and Bromme, D. Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate. J Biol Chem 2002, 277: 28669-76.
72. Dodds, R.A., Connor, J.R., Drake, F., Feild, J. and Gowen, M. Cathepsin K mRNA detection is restricted to osteoclasts during fetal mouse development. J Bone Miner Res 1998, 13: 673-82.
73. Littlewood-Evans, A., Kokubo, T., Ishibashi, O. et al. Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. Bone 1997, 20: 81-6.
74. Punturieri, A., Filippov, S., Allen, S. et al. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J Exp Med 2000, 192: 789-99.
75. Ash, P., Loutit, J.F. and Townsend, K.M. Osteoclasts derived from haematopoietic stem cells. Nature 1980, 283: 669-70.
76. Khapli, S.M., Mangashetti, L.S., Yogesha, S.D. and Wani, M.R. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappaB ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. J Immunol 2003, 171: 142-51.
77. Sukhova, G.K., Shi, G.P., Simon, D.I., Chapman, H.A. and Libby, P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998, 102: 576-83.
78. Shalhoub, V., Faust, J., Boyle, W.J. et al. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. J Cell Biochem 1999, 72: 251-61.
79. Hsu, H., Lacey, D.L., Dunstan, C.R. et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999, 96: 3540-5.
80. Blair, H.C., Sidonio, R.F., Friedberg, R.C., Khan, N. and Dong, S.S. Proteinase expression during differentiation of human osteoclasts in vitro. J Cell Biochem 2000, 78: 627-37.
81. Corisdeo, S., Gyda, M., Zaidi, M., Moonga, B.S. and Troen, B.R. New insights into regulation of cathepsin K gene expression by osteoprotegerin ligand. Biochem Biophys Res Commun 2001, 285: 335-9.
82. Buhling, F., Gerber, A., Hackel, C. et al. Expression of cathepsin K in lung epithelial cells. Am J Respir Cell Mol Biol 1999, 20: 612-9.
83. Buhling, F., Waldburg, N., Gerber, A. et al. Cathepsin K expression in human lung. Adv Exp Med Biol 2000, 477: 281-6.
84. Tepel, C., Bromme, D., Herzog, V. and Brix, K. Cathepsin K in thyroid epithelial cells: Sequence, localization and possible function in extracellular proteolysis of thyroglobulin. J Cell Sci 2000, 113(Pt 24): 4487-98.
85. Hummel, K.M., Petrow, P.K., Franz, J.K. et al. Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J Rheumatol 1998, 25: 1887-94.
86. Littlewood-Evans, A.J., Bilbe, G., Bowler, B.W. et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 1997, 57: 5386-90.
87. Bromme, D. and Okamoto, K. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Biol Chem Hoppe Seyler 1995, 376: 379-84.
88. Haeckel, C., Krueger, S., Kuester, D. et al. Expression of cathepsin K in chordoma. Hum Pathol 2000, 31: 834-40.
89. Haeckel, C., Krueger, S., Buehling, F. et al. Expression of cathepsin-K, in the human embryo and fetus. Dev Dyn 1999, 216: 89-95.
90. Rocken, C., Stix, B., Bromme, D., Ansorge, S., Roessner, A. and Buhling, A. A putative role for cathepsin K in degradation of AA and AL amyloidosis. Am J Pathol 2001, 158: 1029-38.
91. Seemayer, C.A., Kuchen, S., Kuenzler, P. et al. Cartilage destruction mediated by synovial fibroblasts does not depend on proliferation in rheumatoid arthritis. Am J Pathol 2003, 162: 1549-57.
92. Brubaker, K.D., Vessella, R.L., True, L.D., Thomas, R. and Corey, E. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 2003, 18: 222-30.
93. Komine, M., Kukita, A., Kukita, T., Ogata, Y., Hotokebuchi, T. and Kohashi, O. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted ral bone marrow cell culture. Bone 2001, 28: 474-83.
94. Motyckova, G., Weilbaecher, K.N., Horstmann, M., Rieman, D.J., Fisher, D.Z. and Fisher, D.E. Linking osteopetrosis and pycnodysostosis: Regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc Natl Acad Sci USA 2001, 98: 5798-803.
95. Mano, H., Kimura, C., Fujisawa, Y. et al. Cloning and function of rabbit peroxisome proliferator-activated receptor delta/beta in mature osteoclasts. J Biol Chem 2000, 275: 8126-32.
96. Kurata, K., Uemura, T., Nemoto, A. et al. Mechanical strain effect on bone-resorbing activity and messenger RNA expressions of marker enzymes in isolated osteoclast culture. J Bone Miner Res 2001, 16: 722-30.
97. Uemura, T., Liu, Y.K. and Kuboki, Y. Preliminary communication. MRNA expression of MTI-MMP, MMP-9, cathepsin K, and TRAP in highly enriched osteoclasts cultured on several matrix proteins and ivory surfaces. Biosci Biotechnol Biochem 2000, 64: 1771-3.
98. Wittrant, Y., Couillaud, S., Theoleyre, S., Dunstan, C., Heymann, D. and Redini, F. Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochem Biophys Res Commun 2002, 293: 38-44.
99. Mano, H., Yuasa, T., Kameda, T. et al. Mammalian mature osteoclasts as estrogen target cells. Biochem Biophys Res Commun 1996, 223: 637-42.
100. Furuyama, N. and Fujisawa, Y. Regulation of collagenolytic cysteine protease synthesis by estrogen in osteoclasts. Steroids 2000, 65: 371-8.
101. Kamolmatyakul, S., Chen, W. and Li, Y.P. Interferon-gamma down-regulates gene expression of cathepsin K in osteoclasts and inhibits osteoclast formation. J Dent Res 2001, 80: 351-5.
102. Rahman, M.M., Kukita, A., Kukita, T., Shobuike, T., Nakamura, T. and Kohashi, O. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 2003, 101: 3451-9.
103. Kawaida, R., Ohtsuka, T., Okutsu, J. et al. Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL. J Exp Med 2003, 197: 1029-35.
104. Gelb, B.D., Shi, J.P., Chapman, H.A. and Desnick, R.J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996, 273: 1236-8.
105. Gelb, B.D., Edelson, J.G. and Desnick, R.J. Linkage of pycnodysostosis to chromosome 1q21 by homozygosity mapping. Nat Genet 1995, 10: 235-7.
106. Polymeropoulos, M.H., Ortiz De Luna, R.I., Ide, S.E., Torres, R., Rubenstein, J. and Francomano, C.A. The gene for pycnodysostosis maps to human chromosome 1 ceu-q21. Nat Genet 1995, 10: 238-9.
107. Motyckova, G. and Fisher, D.E. Pycnodysostosis: Role and regulation of cathepsin K in osteoclast function and human disease. Curr Mol Med 2002, 2: 407-21.
108. Edelson, J.G., Obad, S., Geiger, R., On, A. and Artul, H.J. Pycnodysostosis. Orthopedic aspects with a description of 14 new cases. Clin Orthop 1992: 263-76.
109. Maroteaux, P. and Lamy, M. La pycnodisostose. Presse Med 1962, 70: 999.
110. Maroteaux, P. and Lamy, M. The malady of Toulouse-Lautrec. JAMA 1965, 191: 715.
111. Johnson, M.R., Polymeropoulos, M.H., Vos, H.L., Ortiz de Luna, R.I. and Francomano, C.A. A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis. Genome Res 1996, 6: 1050-5.
112. Hou, W.S., Bromme, D., Zhao, Y. et al. Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. J Clin Invest 1999, 103: 731-8.
113. Ho, N., Punturieri, A., Wilkin, D. et al. Mutations of CTSK result in pycnodysostosis via a reduction in cathepsin K protein. J Bone Miner Res 1999, 14: 1649-53.
114. Gowen, M., Lazner, F., Dodds, R. et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999, 14: 1654-63.
115. Everts, V., Saftig, P., Korper, W., Delaisse, J.M., Bromme, D. and Beertsen, W. Cathepsin K is more essential for long bone resorption than for resoption of Calvarial bone. J Bone Mineral Res 1999, 14(Suppl I): S356.
116. Everts, V., Korper, W., Jansen, D.C. et al. Functional heterogeneity of osteoclasts: Matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone. FASEB J 1999, 13: 1219-30.
117. Kiviranta, R., Morko, J., Uusitalo, H., Aro, H.T., Vuorio, E. and Rantakokko, J. Accelerated turnover of metaphyseal trabecular bone im mice overexpressing cathepsin K. J Bone Miner Res 2001, 16: 1444-52.
118. Hart, K.A., Potts, W., Bowyer, J. et al. Transgenic mice lacking cathepsin L activity. J Back Musculoskeletal Rehabil 1996, 11(Suppl 1): S181.
119. Reinheckel, T., Deussing, J., Roth, W. and Peters, C. Towards specific functions of lysosomal cysteine peptidases: Phenotypes of mice deficient for cathepsin B or cathepsin L. Biol Chem 2001, 382: 735-41.
120. Moran, M.T., Schofield, J.P., Hayman, A.R., Shi, G.P., Young, E. and Cox, T.M. Pathologic gene expression in Gaucher disease: Up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 2000, 96: 1969-78.
121. Inui, T., Ishibashi, O., Inaoka, T. et al. Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J Biol Chem 1997, 272: 8109-12.
122. Furuyama, N. and Fujisawa, Y. Distinct roles of cathepsin K and cathepsin L in osteoclastic bone resorption. Endocr Res 2000, 26: 189-204.
123. Ishikawa, T., Kamiyama, M., Tani-Ishii, N. et al. Inhibition of osteoclast differentiation and bone resorption by cathepsin K antisense oligonucleotides. Mol Carcinog 2001, 32: 84-91.
124. Delaisse, J.M., Eeckhout, Y. and Vaes, G. In vivo and in vitro evidence for the involvement of cysteine proteinases in bone resorption. Biochem Biophys Res Commun 1984, 125: 441-7.
125. Delaisse, J.M., Boyde, A., Maconnachie, E. et al. The effects of inhibitors of cysteine-proteinases and collagenase on the resorptive activity of isolated osteoclasts. Bone 1987, 8: 305-13.
126. Everts, V., Delaisse, J.M., Korper, W., Niehof, A., Vaes, G. and Beertsen, W. Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases. J Cell Physiol 1992, 150: 221-31.
127. Lerner, U.H. and Grubb, A. Human cystatin C, a cysteine proteinase inhibitor, inhibits bone resorption in vitro stimulated by parathyroid hormone and parathyroid hormone-related peptide of malignancy. J Bone Miner Res 1992, 7: 433-40.
128. Rifkin, B.R., Vernillo, A.T., Kleckner, A.P., Auszmann, J.M., Rosenberg, L.R. and Zimmerman, M. Cathepsin B and L activities in isolated osteoclasts. Biochem Biophys Res Commun 1991, 179: 63-9.
129. Kakegawa, H., Nikawa, T., Tagami, K. et al. Participation of cathepsin L on bone resorption. FEBS Lett 1993, 321: 247-50.
130. Sahara, T., Itoh, K., Debari, K. and Sasaki, T. Specific biological functions of vascuolar-type H+-ATPase and lysosomal cysteine proteinase, cathepsin K. in osteoclasts. Anat Rec 2003, 270A: 152-61.
131. Votta, B.J., Levy, M.A., Badger, A. et al. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J Bone Miner Res 1997, 12: 1396-406.
132. Xia, L., Kilb, J., Wex, H. et al. Localization of rat cathepsin K in osteoclasts and resorption pits: Inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones. Biol Chem 1999, 380: 679-87.
133. James, I.E., Marquis, R.W., Blake, S.M. et al. Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro. J Biol Chem 2001, 276: 11507-11.
134. Katunuma, N., Matsui, A., Inubushi, T. et al. Structure-based development of pyridoxal propionate derivatives as specific inhibitors of cathepsin K in vitro and in vivo. Biochem Biophys Res Commun 2000, 267: 850-4.
135. Bossard, M.J., Tomaszek, T.A., Levy, M.A. et al. Mechanism of inhibition of cathepsin K by potent, selective 1,5-diacylcarbohydrazides: A new class of mechanism-based inhibitors of thiol proteases. Biochemistry 1999, 38: 15893-902.
136. Marquis, R.W., Ru, Y., LoCastro, S.M. et al. Azepanone-based inhibitors of human and rat cathepsin K. J Med Chem 2001, 44: 1380-95.
137. Marquis, R.W., Ru, Y., Yamashita, D.S. et al. Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K. Bioorg Med Chem 1999, 7: 581-8.
138. Bromme, D. and Kaleta, J. Thiol-dependent cathepsins: Pathophysiological implications and recent advances in inhibitor design. Curr Pharm Des 2002, 8: 1639-58.
139. Leung-Toung, R., Li, W., Tam, T.F. and Karimian, K. Thiol-dependent enzymes and their inhibitors: A review. Curr Med Chem 2002, 9: 979-1002.
140. Stroup, G.B., Lark, M.W., Veber, D.F. et al. Potent and selective inhibition of human Cathepsin K leads to inhibition of bone resorption in vivo in a non-human primate. J Bone Miner Res 2001, 16: 1739-46.
141. Stroup, G.B., Hoffman, S.J., Vasko-Moser, J.A. et al. Changes in bone turnover following gonadotropin-releasing hormone (GnRH) agonist administration and estrogen treatment in cynomolgus monkeys: A short-term model for evaluation of antiresorptive therapy. Bone 2001, 28: 532-7.
142. McQueney, M.S., Feild, J., Hanning, C.R. et al. Cynomolgus monkey (Macaca fascicularis) cathepsin K: Cloning, expression, purification, and activation. Protein Expr Purif 1998, 14: 387-94.
143. Reid, I.R., Brown, J.P., Burckhardt, P. et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346: 653-61.
144. Orwoll, E.S., Scheele, W.H., Paul, S. et al. The effect of teriparatide [human parathyroid hormone (I-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18: 9-17.
145. Marcus, R., Wang, O., Satterwhite, J. and Mitlak, B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18: 18-23.